Fatal encephalopathy after pembrolizumab treatment for advanced non-small cell lung carcinoma
- 44 Downloads
To the Editor,
Pembrolizumab is a monoclonal antibody against programmed cell death 1 (PD-1) receptor approved for PD-L1 positive advanced non-small cell lung cancer (NSCLC) . Neurologic adverse events associated with anti-PD1 antibodies are rare . We report a case of fatal encephalopathy in a patient with advanced NSCLC treated with pembrolizumab.
Compliance with ethical standards
Conflict of interest
All authors declare no conflict of interest.
The report of this case was approved by Ethics Committee of Centro Hospitalar e Universitário de São João.
- 3.Feng S, Coward J, McCaffrey E et al (2017) Pembrolizumab-induced encephalopathy: a review of neurological toxicities with immune checkpoint inhibitors. J. Thorac, OncolGoogle Scholar